Form 4: NeoGenomics CFO Acquires $150,000 in Company Stock
SEC Form 4 Filing
Jeffrey Scott Sherman, CFO of NeoGenomics, recently purchased 20,000 shares of the company's common stock at a price of $7.5052 per share.
Summary
- Jeffrey Scott Sherman, the Chief Financial Officer of NeoGenomics, acquired 20,000 shares of common stock on May 2, 2025, at a price of $7.5052 per share.
- This transaction increased Sherman's direct holdings to 158,494 shares.
- The filing also details Sherman's holdings of various derivative securities, including stock options and restricted stock units, with different vesting schedules and exercise prices.
Sentiment
Score: 6
Explanation: The sentiment is neutral to slightly positive. The CFO's purchase indicates confidence, but it's a single transaction and doesn't provide a comprehensive view of the company's overall health.
Positives
- The CFO's purchase of company stock could be interpreted as a sign of confidence in the company's future prospects.
Industry Context
Insider buying is often viewed positively by investors, as it suggests that a company's management believes the stock is undervalued and has confidence in the company's future performance. However, it's important to consider the size of the purchase relative to the executive's overall holdings and the company's market capitalization.
Comparison to Industry Standards
- Comparing the vesting schedules and option grants to similar companies in the diagnostics or biotechnology sectors would provide context on whether these compensation packages are standard.
- Companies like Exact Sciences, Guardant Health, or Invitae could be used as benchmarks for comparison.
Stakeholder Impact
- The CFO's stock purchase could positively influence shareholder sentiment.
Key Dates
| Date | Description |
|---|---|
| 12/05/2022 | Mr. Sherman was granted 249,169 stock options. |
| 12/07/2023 | First tranche vesting date for stock options granted on December 5, 2022. |
| 05/11/2023 | Mr. Sherman was granted 73,016 stock options and 39,016 restricted stock units. |
| 02/23/2024 | Mr. Sherman was granted 77,913 stock options and 46,606 performance stock units. |
| 02/20/2025 | Closing price used to calculate the premium exercise price for stock options granted on February 21, 2025. |
| 02/21/2025 | Mr. Sherman was granted 214,900 stock options and 126,476 restricted stock units. |
| 05/02/2025 | Date of the transaction where Mr. Sherman acquired 20,000 shares of common stock. |
| 05/06/2025 | Date of the Form 4 filing. |
| 05/11/2026 | Vesting date for performance stock units. |
| 02/23/2027 | Vesting date for performance stock units. |
| 12/05/2029 | Expiration date for stock options. |
| 05/11/2030 | Expiration date for stock options. |
| 02/23/2034 | Expiration date for stock options. |
| 02/21/2035 | Expiration date for stock options. |
Keywords
NeoGenomics, Insider Trading, Form 4, Stock Options, Restricted Stock Units, Beneficial Ownership, CFO, Jeffrey Scott Sherman, NEO
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.